Journal
METABOLITES
Volume 12, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/metabo12050417
Keywords
bile acids; bariatric surgery; Roux-en-Y gastric bypass; weight response; gut microbiota
Categories
Funding
- German Federal Ministry of Education and Research (BMBF), Germany, IFB Adiposity Diseases [FKZ: 01EO1501]
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [TRR333/1, AOBJ: 450149205, AOBJ: 624808, AOBJ:667675, AOBJ: 676866]
- Else Kroener Fresenius Foundation
- IFB Adiposity Disease by the German Federal Ministry of Education and Research (BMBF)
- DFG [403224013-SFB 1382-A05]
- Novo Nordisk Foundation [NNF21OC0066551]
- UFZ
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) via Collaborative Research Center (CRC) 1052
Ask authors/readers for more resources
Extreme weight responders to Roux-en-Y gastric bypass (RYGB) surgery exhibit differences in their metabolic outcomes and gut microbiota composition. Differences in weight loss did not reflect in metabolic outcome after RYGB. Fecal and circulating metabolite analyses showed variations in metabolite levels between different weight responders.
Background: Roux-en-Y gastric bypass (RYGB) surgery belongs to the most frequently performed surgical therapeutic strategies against adiposity and its comorbidities. However, outcome is limited in a substantial cohort of patients with inadequate primary weight loss or considerable weight regain. In this study, gut microbiota composition and systemically released metabolites were analyzed in a cohort of extreme weight responders after RYGB. Methods: Patients (n = 23) were categorized based on excess weight loss (EWL) at a minimum of two years after RYGB in a good responder (EWL 93 +/- 4.3%) or a bad responder group (EWL 19.5 +/- 13.3%) for evaluation of differences in metabolic outcome, eating behavior and gut microbiota taxonomy and metabolic activity. Results: Mean BMI was 47.2 +/- 6.4 kg/m(2) in the bad vs. 26.6 +/- 1.2 kg/m(2) in the good responder group (p = 0.0001). We found no difference in hunger and satiety sensation, in fasting or postprandial gut hormone release, or in gut microbiota composition between both groups. Differences in weight loss did not reflect in metabolic outcome after RYGB. While fecal and circulating metabolite analyses showed higher levels of propionate (p = 0.0001) in good and valerate (p = 0.04) in bad responders, respectively, conjugated primary and secondary bile acids were higher in good responders in the fasted (p = 0.03) and postprandial state (GCA, p = 0.02; GCDCA, p = 0.02; TCA, p = 0.01; TCDCA, p = 0.02; GDCA, p = 0.05; GUDCA, p = 0.04; TLCA, p = 0.04). Conclusions: Heterogenous weight loss response to RYGB surgery separates from patients' metabolic outcome, and is linked to unique serum metabolite signatures post intervention. These findings suggest that the level of adiposity reduction alone is insufficient to assess the metabolic success of RYGB surgery, and that longitudinal metabolite profiling may eventually help us to identify markers that could predict individual adiposity response to surgery and guide patient selection and counseling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available